Related Experiment Videos
[Fundamental and clinical evaluation of ceftriaxone in the pediatric field]
Insights
Ceftriaxone (CTRX) shows high efficacy against pediatric bacterial infections, including resistant strains. Twice-daily dosing is safe and effective, though vitamin K deficiency monitoring is advised.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antimicrobial Susceptibility
Context:
- Pediatric bacterial infections pose significant health challenges.
- Evaluating novel antibiotic options is crucial for effective treatment.
- Ceftriaxone (CTRX) is a third-generation cephalosporin with broad-spectrum activity.
Purpose:
- To assess the fundamental and clinical efficacy of ceftriaxone in pediatric patients.
- To determine the antimicrobial susceptibility of pediatric isolates to CTRX.
- To evaluate the safety and tolerability of CTRX in children.
Summary:
- Ceftriaxone demonstrated potent activity against E. coli from pediatric urinary tract infections (UTIs), with MICs ≤0.39 mcg/ml.
- CTRX outperformed other cephalosporins (CPZ, LMOX) and was effective against ampicillin-resistant bacteria.
- Clinical and bacteriological efficacy rates were 83% and 100%, respectively, in pediatric respiratory tract and UTI cases.
Impact:
- Ceftriaxone (CTRX) is a valuable therapeutic option for pediatric bacterial infections.
- Twice-daily administration of CTRX (20 mg/kg) is considered safe and effective.
- Monitoring for potential vitamin K deficiency is recommended during CTRX therapy.
Abstract:
Fundamental and clinical evaluation of ceftriaxone (CTRX) was performed in the pediatric field and the following results were obtained. The MIC of CTRX against E. coli isolated from urinary tract infections in children ranged from less than or equal to 0.024 to 0.39 mcg/ml except for 1 strain. CTRX was superior to other 3rd generation cephalosporins such as CPZ and LMOX, showing effectiveness also against ABPC-resistant bacteria. The clinical efficacy and bacteriological efficacy in 6 children consisting of 5 with respiratory tract infections and 1 with urinary tract infection were 83% and 100%, respectively. As to the adverse reaction, diarrhea was observed in 2 cases. The determination of PIVKA-II performed during the therapy with CTRX, which is observed when vitamin K is deficient, showed positiveness in 2 cases out of 6 cases including 1 which the clinical efficacy could not be evaluated. The test of platelet function in 3 cases found no inhibition of agglutination. Twice-daily administration with 20 mg/kg CTRX was considered to be a useful and safe method for treatment of bacterial infections in children, although attention should be taken not to cause vitamin K deficiency as in other 2nd and 3rd generation cephalosporins.